Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Suvorexant for the treatment of insomnia
Laura H. Jacobson, Gabrielle E. Callander, Daniël Hoyer
Expert Review of Clinical Pharmacology (2014) Vol. 7, Iss. 6, pp. 711-730
Closed Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery
Karol Biernacki, Mateusz Daśko, Olga Ciupak, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 6, pp. 111-111
Open Access | Times Cited: 139
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies
Elena Urrestarazu, Jorge Iriarte
Nature and Science of Sleep (2016), pp. 21-21
Open Access | Times Cited: 102
Role of the Orexin/Hypocretin System in Stress-Related Psychiatric Disorders
Morgan H. James, Erin J. Campbell, Christopher V. Dayas
Current topics in behavioral neurosciences (2017), pp. 197-219
Open Access | Times Cited: 102
The 1,2,3-triazole ‘all-in-one’ ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool
Deniz Lengerli, Kübra İbiş, Yahya Nural, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 11, pp. 1209-1236
Closed Access | Times Cited: 52
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease
Nina Divorty, Amanda E. Mackenzie, Stuart A. Nicklin, et al.
Frontiers in Pharmacology (2015) Vol. 6
Open Access | Times Cited: 87
Effects of orexin receptor antagonism on human sleep architecture: A systematic review
Jacob Clark, Maddison L. Brian, Sean P. A. Drummond, et al.
Sleep Medicine Reviews (2020) Vol. 53, pp. 101332-101332
Closed Access | Times Cited: 54
Orexin Signaling: A Complex, Multifaceted Process
Natasha C. Dale, Daniël Hoyer, Laura H. Jacobson, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 26
Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities
Matteo Carpi, Laura Palagini, Mariana Fernandes, et al.
Neuropharmacology (2023) Vol. 245, pp. 109815-109815
Open Access | Times Cited: 15
Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia
Andrew Hogyu Han, Caroline R. Burroughs, Evan P. Falgoust, et al.
Health psychology research (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 13
Obstructive sleep apnea syndrome, orexin, and sleep–wake cycle: The link with the neurodegeneration
Mariana Fernandes, Claudio Liguori
Handbook of clinical neurology (2025), pp. 141-160
Closed Access
The Effect of Suvorexant on Fear Extinction Recall: A Double‐Blind Randomised Controlled Pilot Trial in Healthy Individuals
Maya T. Schenker, Lilith Z. Zeng, J Lynskey, et al.
Journal of Sleep Research (2025)
Open Access
Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
Sarah L. Anderson, Jessica Norman
Nature and Science of Sleep (2016) Vol. Volume 8, pp. 239-247
Open Access | Times Cited: 44
Triethylene glycol, an active component of Ashwagandha (Withania somnifera) leaves, is responsible for sleep induction
Mahesh K. Kaushik, Sunil C. Kaul, Renu Wadhwa, et al.
PLoS ONE (2017) Vol. 12, Iss. 2, pp. e0172508-e0172508
Open Access | Times Cited: 44
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications
W. Joseph Herring, Thomas Roth, Andrew D. Krystal, et al.
Journal of Sleep Research (2018) Vol. 28, Iss. 2
Closed Access | Times Cited: 44
Enhancing endogenous adenosine A2A receptor signaling induces slow-wave sleep without affecting body temperature and cardiovascular function
Mustafa Korkutata, Tsuyoshi Saitoh, Yoan Chérasse, et al.
Neuropharmacology (2018) Vol. 144, pp. 122-132
Open Access | Times Cited: 41
Orexin Depolarizes Central Amygdala Neurons via Orexin Receptor 1, Phospholipase C and Sodium-Calcium Exchanger and Modulates Conditioned Fear
Erik T. Dustrude, Izabela Facco Caliman, Cristian Bernabe, et al.
Frontiers in Neuroscience (2018) Vol. 12
Open Access | Times Cited: 39
Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference
Jed Black, Giora Pillar, Jan Hedner, et al.
Sleep Medicine (2017) Vol. 36, pp. 86-94
Closed Access | Times Cited: 39
Orexin OX2 Receptor Antagonists as Sleep Aids
Laura H. Jacobson, Sui Chen, Sanjida Mir, et al.
Current topics in behavioral neurosciences (2016), pp. 105-136
Open Access | Times Cited: 35
Hypnotics with novel modes of action
Daniël Hoyer, Andrew G. Allen, Laura H. Jacobson
British Journal of Clinical Pharmacology (2019) Vol. 86, Iss. 2, pp. 244-249
Open Access | Times Cited: 33
Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial
Thomas C. Neylan, Anne Richards, Thomas J. Metzler, et al.
SLEEP (2020) Vol. 43, Iss. 10
Open Access | Times Cited: 22
Positive allosteric adenosine A2A receptor modulation suppresses insomnia associated with mania- and schizophrenia-like behaviors in mice
Lin Yang, Koustav Roy, Shuji Ioka, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Optimization of Human Dose Prediction by Using Quantitative and Translational Pharmacology in Drug Discovery
Tjerk Bueters, Christopher R. Gibson, Sandra A. G. Visser
Future Medicinal Chemistry (2015) Vol. 7, Iss. 17, pp. 2351-2369
Closed Access | Times Cited: 24
Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts
Jeremy Petrous, Kevin M. Furmaga
BMJ Case Reports (2017), pp. bcr-222037
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top